Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EZH2 | Q15910 | 18/20 | 0.58 |
| ▸ | EED | O75530 | 11/20 | 0.53 |
| ▸ | RBBP4 | Q09028 | 11/20 | 0.53 |
| ▸ | SUZ12 | Q15022 | 11/20 | 0.53 |
| ▸ | AEBP2 | Q6ZN18 | 11/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14972300 | 1.00 | EZH2 (0.58) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL14972304 | 1.00 | EZH2 (0.58) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL14972329 | 0.92 | EZH2 (0.59) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL14972323 | 0.92 | EZH2 (0.56) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL14972332 | 0.91 | EZH2 (0.53) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL14972053 | 0.90 | EZH2 (0.57) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL14972050 | 0.90 | EZH2 (0.57) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL14972326 | 0.90 | EZH2 (0.57) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL14972047 | 0.90 | EZH2 (0.56) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL19180116 | 0.90 | EZH2 (0.59) | EZH2EEDRBBP4SUZ12AEBP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9206128-B2 | Modulators of methyl modifying enzymes, compositions and uses thereof | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2015-12-08 | — | — | US | disclosed |
| US-9206128-B2 | Modulators of methyl modifying enzymes, compositions and uses thereof | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2015-12-08 | — | — | US | disclosed |
| US-20140288123-A1 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. | 2014-09-25 | — | — | US | disclosed |
| WO-2013075083-A1 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS (US) | 2013-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140288123-A1 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | TET1, TET3, EHMT2 | EZH2 61/4885EED 329/4885RBBP4 213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.